Lev Pharmaceuticals' Cinryze®, a prophylaxis against hereditary angioedema (HAE), was approved by the FDA after successful pivotal clinical trials managed by Atlantic Research Group. Families living with the disease are also burdened with the knowledge that the genetic considition is likely to affect their descendants. Sometimes life-threatening swelling of the airway, along with non-life-threatening swelling of the extremities are among the symptoms of the disorder. Our experience enrolling patients on challenging protocols, under very strict and high-pressure enrollment timelines (especially for conditions with low patient populations, e.g. HAE) is one of our greatest strengths.
Jason Bablak, Lev’s Vice President of Regulatory Affairs & Product Development